Drug Profile
Rezvilutamide - Jiangsu Hengrui Medicine Co.
Alternative Names: Ariane; SHR-3680Latest Information Update: 09 Apr 2024
Price :
$50
*
At a glance
- Originator Jiangsu Hengrui Medicine Co.
- Developer Beijing Biote Pharmaceutical; Jiangsu Hengrui Medicine Co.; Peking University First Hospital
- Class Alcohols; Antineoplastics; Benzonitrile; Fluorinated hydrocarbons; Imidazolidines; Ketones; Organic sulfur compounds; Phenyl ethers; Small molecules
- Mechanism of Action Androgen receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Prostate cancer
- Phase II Salivary gland cancer
Most Recent Events
- 30 Mar 2024 Phase-II clinical trials in Salivary gland cancer (Adjuvant therapy, Combination therapy, Late-stage disease) in China (PO) (NCT06348264)
- 20 Oct 2023 Efficacy data from a phase III CHART trial in Prostate cancer presented at the 48th European Society for Medical Oncology Congress (ESMO-2023)
- 26 Apr 2023 Jiangsu Hengrui Medicine initiates enrolment in a phase I trial for Prostate cancer (In adults, In the elderly, Hormone refractory, Metastatic disease, Second-line therapy or greater) in China (PO, Tablet) (NCT05607693)